非瓣膜性房颤患者应用利伐沙班和华法林治疗效果的对比分析  

Comparison of clinical effects and adverse reactions between rivaroxaban and warfarin in the treatment of non-valvular atrial fibrillation

作　　者：王颖[1] Wang Ying(Department of Cardiology,Third People's Hospital of Nantong,Jiangsu Province,Nantong 226001,China)

机构地区：[1]江苏省南通市第三人民医院心内科,226001

出　　处：《现代养生》2021年第20期44-46,共3页Health Protection and Promotion

摘　　要：目的对比分析非瓣膜性房颤患者应用利伐沙班与华法林治疗效果的差异。方法选择医院2017年1月—2020年6月诊治的160例非瓣膜性房颤患者为研究对象。根据组间基本资料均衡可比的原则分为观察组和对照组,每组80例。观察组应用利伐沙班治疗,对照组应用华法林治疗。结果治疗前两组患者凝血酶原时间(PT)、活化部分凝血活酶时间(APTT)、凝血酶时间(TT)及国际标准化比值(INR)比较差异均无统计学意义(P>0.05);治疗1年后,两组患者以上指标均延长,且观察组PT、TT、APTT和INR均高于对照组(P<0.05);观察组出血事件发生率为3.75%,栓塞事件发生率为2.50%,低于对照组12.50%和11.25%,差异均有统计学意义(P<0.05);两组不良反应发生率分别为13.75%和12.50%,差异无统计学意义(P>0.05)。结论利伐沙班治疗非瓣膜性房颤较华法林抗凝效果好,降低出血及栓塞事件,不增加不良反应。Objective To compare and analyze the therapeutic effects of rivaroxaban and warfarin in patients with non valvular atrial fibrillation.Methods A total of 160 patients with non valvular atrial fibrillation treated in the hospital from January 2017 to June 2020 were selected as the research objects.According to the principle of balanced and comparable basic data between groups,they were divided into observation group and control group,with 80 cases in each group.The observation group was treated with rivaroxaban and the control group was treated with warfarin.Results There was no significant difference in PT,APTT,TT and INR between the two groups before treatment(P>0.05);After one year of treatment,the above indexes were prolonged in both groups,and PT,TT,APTT and INR in the observation group were higher than those in the control group(P<0.05);The incidence of bleeding events in the observation group was 3.75%,and the incidence of embolization events was 2.50%,which was lower than 12.50% and 11.25% in the control group(P<0.05);The incidence of adverse reactions in the two groups were 13.75% and 12.50% respectively,and the difference was not statistically significant(P>0.05).Conclusion Rivaroxaban has better anticoagulant effect than warfarin in the treatment of non valvular atrial fibrillation,reduces bleeding and embolism events,and does not increase adverse reactions.

关 键 词：非瓣膜性房颤 利伐沙班 华法林 效果 不良反应 

分 类 号：R541.75[医药卫生—心血管疾病]